Meros Investment Management LP Sells 164,113 Shares of InfuSystem Holdings, Inc. (NYSE:INFU)

Meros Investment Management LP reduced its holdings in InfuSystem Holdings, Inc. (NYSE:INFU - Free Report) by 21.0% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 616,138 shares of the company's stock after selling 164,113 shares during the quarter. InfuSystem comprises 2.0% of Meros Investment Management LP's portfolio, making the stock its 23rd biggest holding. Meros Investment Management LP owned approximately 2.89% of InfuSystem worth $4,208,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently made changes to their positions in the business. Vanguard Group Inc. grew its position in shares of InfuSystem by 1.7% in the first quarter. Vanguard Group Inc. now owns 1,083,730 shares of the company's stock valued at $9,288,000 after purchasing an additional 18,432 shares during the last quarter. Wasatch Advisors LP grew its position in shares of InfuSystem by 3.4% in the fourth quarter. Wasatch Advisors LP now owns 846,609 shares of the company's stock valued at $8,923,000 after purchasing an additional 27,881 shares during the last quarter. Ranger Investment Management L.P. lifted its stake in shares of InfuSystem by 4.7% in the fourth quarter. Ranger Investment Management L.P. now owns 689,842 shares of the company's stock valued at $7,271,000 after buying an additional 30,835 shares during the period. First Eagle Investment Management LLC lifted its stake in shares of InfuSystem by 10.0% in the second quarter. First Eagle Investment Management LLC now owns 666,048 shares of the company's stock valued at $4,549,000 after buying an additional 60,813 shares during the period. Finally, Bank of New York Mellon Corp lifted its stake in shares of InfuSystem by 6.1% in the second quarter. Bank of New York Mellon Corp now owns 93,899 shares of the company's stock valued at $641,000 after buying an additional 5,391 shares during the period. 71.13% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on the stock. StockNews.com upgraded shares of InfuSystem from a "buy" rating to a "strong-buy" rating in a research note on Friday, September 20th. B. Riley assumed coverage on shares of InfuSystem in a research note on Thursday. They issued a "buy" rating and a $13.00 target price for the company.

InfuSystem Stock Up 2.9 %

Shares of NYSE INFU traded up $0.19 during mid-day trading on Friday, hitting $6.75. The company had a trading volume of 49,509 shares, compared to its average volume of 56,383. The stock has a market cap of $143.91 million, a PE ratio of -693,000.00 and a beta of 1.46. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.64 and a current ratio of 2.07. InfuSystem Holdings, Inc. has a 12 month low of $5.74 and a 12 month high of $10.99.

InfuSystem (NYSE:INFU - Get Free Report) last announced its quarterly earnings results on Thursday, August 8th. The company reported $0.03 EPS for the quarter, missing analysts' consensus estimates of $0.04 by ($0.01). The business had revenue of $33.70 million for the quarter. InfuSystem had a return on equity of 0.70% and a net margin of 0.28%.

About InfuSystem

InfuSystem Holdings, Inc, through its subsidiaries, provides infusion pumps, and related products and services in the United States and Canada. The company operates in two segments, Patient Services and Device Solutions. It supplies electronic ambulatory infusion pumps and associated disposable supply kits to oncology, infusion, and hospital outpatient chemotherapy clinics for the treatment of various cancers, including colorectal cancer, pain management, and other disease states.